Top broker tips huge returns from the Inghams (ASX:ING) share price

The Inghams Group Ltd (ASX:ING) share price is on form and has been tipped to climb materially higher from here by a leading broker…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Inghams Group Ltd (ASX: ING) share price has been a positive performer again on Monday.

In afternoon trade, the poultry producer's shares are up 3.5% to $3.53.

This means the Inghams share price is now up 12% over the last two trading sessions.

blue arrows representing a rising share price ASX 200

Image source: Getty Images

Why is the Inghams share price charging higher?

Investors have been bidding the Inghams share price higher since the release of its FY 2021 guidance on Friday.

For the 12 months ending 25 June, Inghams is forecasting statutory earnings before interest, tax, depreciation and amortisation (EBITDA) of $438 million to $448 million and statutory net profit after tax of $80 million to $87 million. This has been driven by the benefits derived from operational efficiencies implemented throughout the year and improved trading conditions.

Management also noted that the guidance was well-ahead of the analyst consensus estimates.

Can its shares keep on climbing?

One leading broker believes the Inghams share price still has a long way to run from here.

According to a note out of Goldman Sachs, its analysts have retained their buy rating and lifted their price target on the company's shares to $4.50.

Based on its current share price, this implies potential upside of 27% over the next 12 months excluding dividends. And if you include dividends, this potential return stretches to ~34%.

What did Goldman say?

Goldman commented: "The ANZ Poultry market is improving and ING has issued a positive trading update as we head to a close in FY21. We have upgraded our FY21-FY23 EBITDA by +2-5% and EPS by +2-11%. While today's announcement is specific to FY21 profitability, we expect some flow through to future years from the high earnings base. Our 12-month TP has increased +5% to A$4.50, implying 39% [prior to today] total return potential. We retain our Buy rating."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man looking at his laptop and thinking.
Broker Notes

Buy, hold, sell: What this leading broker is saying about Lynas shares

Is it bullish or bearish? Let's find out.

Read more »

share buyers, investors, happy investors
Broker Notes

Bell Potter's top ASX 200 holdings revealed

These are the top holdings in the broker's core portfolio.

Read more »

An athlete runs fast with a trail of yellow smoke billowing out behind him.
Broker Notes

Up 139% in a year, why this buy rated ASX All Ords rare earths stock could keep racing higher

A leading broker forecasts more outperformance to come from this surging ASX rare earths stock.

Read more »

Miner with thumbs up at a mine.
Gold

2 ASX gold miners to buy for solid share price gains, according to Barrenjoey

The Africa-focused companies are deeply undervalued after recent sell-offs, the broker says.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »